Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994584 | 1.00 | MEN1 (0.53) | MEN1GAAKMT2AGFPT1TDP1 | |
| SCHEMBL997508 | 1.00 | MEN1 (0.53) | MEN1GAAKMT2AGFPT1TDP1 | |
| Hydrochloric Acid SCHEMBL2680968 | 0.98 | MEN1 (0.51) | MEN1GAAKMT2AGFPT1TDP1 | |
| Hydrochloric Acid SCHEMBL668972 | 0.98 | MEN1 (0.51) | MEN1GAAKMT2AGFPT1TDP1 | |
| Hydrochloric Acid SCHEMBL2681229 | 0.98 | MEN1 (0.51) | MEN1GAAKMT2AGFPT1TDP1 | |
| Chloromethane SCHEMBL17911911 | 0.98 | MEN1 (0.51) | MEN1GAAKMT2AGFPT1TDP1 | |
| Formic Acid SCHEMBL7370577 | 0.93 | MEN1 (0.47) | MEN1GAAKMT2AGFPT1TDP1 | |
| SCHEMBL23455458 | 0.89 | MEN1 (0.46) | MEN1GAAKMT2AGFPT1TDP1 | |
| SCHEMBL23455605 | 0.89 | MEN1 (0.46) | MEN1GAAKMT2AGFPT1TDP1 | |
| SCHEMBL13365413 | 0.86 | MEN1 (0.47) | MEN1GAAKMT2AGFPT1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| EP-4615509-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615511-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615510-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-0832077-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996037482-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0304087-B1 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER LAMBERT CO (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MEN1 2253/4885GAA 3682/4885KMT2A 1052/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | MEN1 104/4885GAA 3324/4885KMT2A 3390/4885 |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | CTDSP1, POLM, MCTS1 | MEN1 2576/4885GAA 1789/4885KMT2A 1926/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | MEN1 3617/4885GAA 1998/4885KMT2A 1621/4885 |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, MALT1, LY6K | MEN1 385/4885GAA 3674/4885KMT2A 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.